Hypomethylating Agents and the Treatment of MDS
Myelodysplastic syndromes are a group of blood cancers where the bone marrow fails to produce healthy blood cells. Treatment options are limited—especially for older patients. Hypomethylating agents like decitabine offer a valuable option, and their role is shaping the decitabine drug market. Within the Decitabine Drug Market, MDS is a major application. The commercial implications favor...
0 Comments 0 Shares 2 Views 0 Reviews